by barry101 | Jul 13, 2021 | Press Releases
– Protocol amendment allows for change in dose limiting toxicity (DLT) criteria for future enrolled subjects- Demonstrated efficacy in 240 mg/m² cohort with Annamycin- Annamycin has demonstrated little to no cardiotoxicity, avoids multidrug resistance, has...
by barry101 | Jun 21, 2021 | Press Releases
– Annamycin granted Fast Track Status and Orphan Drug Designation from FDA for the treatment of soft tissue sarcoma lung metastases- Interim data expected in the second half of 2022HOUSTON, June 21, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX)...
by barry101 | Jun 15, 2021 | Press Releases
HOUSTON, June 15, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today...
by barry101 | May 25, 2021 | Press Releases
– Annamycin was designed to potentially become the first ever non-cardiotoxic anthracycline and has been shown in animal models to accumulate in the lungs at more than 30 times the level of doxorubicin (current standard of care)- Patient enrollment on track to...
by barry101 | May 12, 2021 | Press Releases
– Multiple ongoing clinical studies expected to drive key clinical and regulatory milestones throughout next 18 months — Significantly strengthened financial position extends cash runway through 2023 -HOUSTON, May 12, 2021 — Moleculin Biotech, Inc.,...
by barry101 | May 11, 2021 | Press Releases
Live video webcast with President and CEO, Walter Klemp, on Monday, May 17, 2021 at 12:30 PM ET HOUSTON, May 11, 2021 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”), a clinical stage pharmaceutical company with a...
